Abstract A35: A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma
Neerav Shukla(Memorial Sloan Kettering Cancer Center), Marc Ladanyi(Memorial Sloan Kettering Cancer Center), Julia A. Bridge(Nebraska Medical Center), Shinji Kohsaka(National Cancer Research Institute), Nabahet Ameur(Bristol-Myers Squibb (France)), Snjezana Doğan(Memorial Sloan Kettering Cancer Center), Agnès Viale(Genomics (United Kingdom)), Angela Yannes(Memorial Sloan Kettering Cancer Center), Leonard H. Wexler(Memorial Sloan Kettering Cancer Center), Raf Sciot(KU Leuven), Li‐Xuan Qin(Memorial Sloan Kettering Cancer Center), Jonathan A. Fletcher(Harvard University), Paul A. Meyers(Memorial Sloan Kettering Cancer Center)
Cited by 1
Related Papers
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k